-
公开(公告)号：US20180250216A1
公开(公告)日：2018-09-06
申请号：US15980184
申请日：2018-05-15
Inventor： Shinn-Zong Lin , Horng-Jyh Harn , Tzyy-Wen Chiou , Po-Cheng Lin
CPC classification number: A61K8/64 , A61F7/02 , A61F2007/0003 , A61F2007/0062 , A61F2007/0088 , A61K8/981 , A61K2800/805 , A61K2800/86 , A61K2800/88 , A61N5/0625 , A61Q7/00 , A61Q19/08
Abstract: A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.
-
12.发明授权Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases 有权增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法公开(公告)号：US09518251B2
公开(公告)日：2016-12-13
申请号：US15074490
申请日：2016-03-18
Inventor： Shinn-Zong Lin , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C12N5/00 , C12N5/02 , C12N5/0775 , A61K35/545 , A61K35/28
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell.
Abstract translation: 提供了增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法。 该方法包括用ligustilide预处理干细胞，以增加干细胞中分化促进基因的表达，增加干细胞中归巢促进基因的表达，和/或减少干细胞中炎症基因的表达 细胞，其中处理在干细胞的培养基中进行。
-
13.发明申请METHOD FOR ENHANCING THERAPEUTIC EFFECT OF STEM CELLS ON AUTOIMMUNE DISEASES, CARDIOVASCULAR DISEASES, AND/OR HEMATOLOGICAL DISEASES 有权干细胞治疗自身免疫性疾病，心血管疾病和/或血液病的治疗方法公开(公告)号：US20160208217A1
公开(公告)日：2016-07-21
申请号：US15074490
申请日：2016-03-18
Inventor： Shinn-Zong LIN , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C12N5/0775
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell.
Abstract translation: 提供了增强干细胞对自身免疫疾病，心血管疾病和/或血液疾病的治疗效果的方法。 该方法包括用ligustilide预处理干细胞，以增加干细胞中分化促进基因的表达，增加干细胞中归巢促进基因的表达，和/或减少干细胞中炎症基因的表达 细胞，其中处理在干细胞的培养基中进行。
-
公开(公告)号：US20240117314A1
公开(公告)日：2024-04-11
申请号：US18376440
申请日：2023-10-03
Inventor： Ruei-Yue Liang , Chia-Hsin Lee , Kai-Ling Zhang , Po-Cheng Lin , Ming-Hsi Chuang , Yu-Chen Tsai , Peggy Leh Jiunn Wong
IPC: C12N5/0775 , A01N1/02 , A61K35/28 , A61P3/10
CPC classification number: C12N5/0662 , A01N1/0284 , A61K35/28 , A61P3/10 , C12N2500/32 , C12N2500/38
Abstract: The present invention relates to a method for preparing a modified stem cell, including the following steps: a cell culture step: culturing stem cells in a first culture medium of a culture dish at a predetermined cell density, and removing the first culture medium after a first culture time to obtain a first cell intermediate; an activity stimulation step: preserving the first cell intermediate in a freezing container having a cell cryopreservation solution, and performing a constant temperature stimulation treatment or a variable temperature stimulation treatment for at least more than 1 day; and a product collection step: after completing the activity stimulation step, placing the freezing container in an environment at a thawing temperature for thawing, and then removing the cell cryopreservation solution to obtain the modified stem cell. The modified stem cell can release at least one or more of IL-4, IL-5, IL-13, G-CSF, Fractalkine, and EGF.
-
公开(公告)号：US20240115616A1
公开(公告)日：2024-04-11
申请号：US18376545
申请日：2023-10-04
Inventor： Po-Cheng Lin , Pi-Chun Huang , Zih-Han Hong , Ming-Hsi Chuang , Yi-Chun Lin , Chia-Hsin Lee , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang
IPC: A61K35/28 , A61K9/00 , A61K9/127 , A61P1/16 , C12N5/0775
CPC classification number: A61K35/28 , A61K9/0019 , A61K9/127 , A61P1/16 , C12N5/0667 , C12N2500/02
Abstract: The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.
-
Patent Agency Ranking
公开(公告)号：US10022313B2
公开(公告)日：2018-07-17
申请号：US14321954
申请日：2014-07-02
Inventor： Shinn-Zong Ling , Horng-Jyh Harn , Tzyy-Wen Chiou , Po-Cheng Lin
Abstract: A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.
-
17.发明授权Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases 有权增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法公开(公告)号：US09523081B2
公开(公告)日：2016-12-20
申请号：US14821309
申请日：2015-08-07
Inventor： Shinn-Zong Lin , Horng-Jyh Harn , Ru-Huei Fu , Shih-Ping Liu , Po-Cheng Lin , Ming-Hsi Chuang
IPC: A01N63/00 , A01N65/00 , C12N5/0775 , A61K35/545 , A61K35/28
CPC classification number: A61K35/28 , A61K31/365 , A61K35/545 , C12N5/0667 , C12N2501/40 , C12N2501/999
Abstract: A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject suffering from autoimmune diseases, cardiovascular diseases, and/or hematological diseases an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
Abstract translation: 提供了一种用于增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法。 该方法包括用罗替司特治疗干细胞，其中处理在干细胞的培养基中进行。 还提供了一种干细胞治疗方法，其包括对患有自身免疫性疾病，心血管疾病和/或血液疾病的受试者施用有效量的干细胞或光灭活素与干细胞的组合，其中所述干细胞具有 用ligustilide治疗。
-
公开(公告)号：US20250144150A1
公开(公告)日：2025-05-08
申请号：US19012977
申请日：2025-01-08
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , A61K38/18 , A61K38/19 , A61K38/20 , A61K45/06 , A61P25/28 , C12N5/00 , C12N5/0775
Abstract: The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
公开(公告)号：US20240075071A1
公开(公告)日：2024-03-07
申请号：US17993823
申请日：2022-11-23
Inventor： Ruei-Yue Liang , Kai-Ling Zhang , Ming-Hsi Chuang , Po-Cheng Lin , Peggy Leh Jiunn Wong , Chia-Hsin Lee
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0667 , C12N2500/32 , C12N2500/38 , C12N2500/60 , C12N2500/90 , C12N2501/115 , C12N2501/15
Abstract: Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell
-
公开(公告)号：US20230407262A1
公开(公告)日：2023-12-21
申请号：US18055409
申请日：2022-11-14
Inventor： Wei Wu Li , Tzyy-Wen Chiou , Horng-Jyh Harn , Shinn-Zong Lin , Ming-Hsi Chuang , Po-Cheng Lin , Chia-Hsin Lee , Mao-Hsuan Huang
IPC: C12N5/0775 , C12N5/079 , C07K14/435 , A61K38/17 , A61P25/00
CPC classification number: C12N5/0663 , C12N5/0618 , C07K14/435 , A61K38/17 , A61P25/00
Abstract: The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.018 seconds)
